Evidence map›Paper›PMID 37850268›Full record

ArticleHLA2024

HLA-DPB1*13:01 associates with enhanced, and KIR2DS4*001 with diminished protection from developing severe COVID-19.

Ticiana D J Farias, Silvia Brugiapaglia, Susanna Croci, Paola Magistroni, Claudia Curcio, Kristina Zguro, Chiara Fallerini, Francesca Fava, Francesco Pettini, Katherine M Kichula and 15 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HLA, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. The Role of Killer Ig-like Receptors in Diseases from A to Z.International journal of molecular sciences · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 2 countries.

Ticiana D J FariasDepartment of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA.ORCID 0000-0002-3606-2428
Silvia BrugiapagliaDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Susanna CrociMedical Genetics, University of Siena, Siena, Italy.
Paola MagistroniImmunogenetics and Transplant Biology, Azienda Ospedaliera Universitaria, Città della Salute e della Scienza di Torino, Turin, Italy.
Claudia CurcioDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
Kristina ZguroMed Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Chiara FalleriniMedical Genetics, University of Siena, Siena, Italy.
Francesca FavaMedical Genetics, University of Siena, Siena, Italy.ORCID 0000-0002-4363-2353
Francesco PettiniMed Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Katherine M KichulaDepartment of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Nicholas R PollockDepartment of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Neus Font-PorteriasDepartment of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA.
William H PalmerDepartment of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Wesley M MarinDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-2334-0396
Margherita BaldassarriMedical Genetics, University of Siena, Siena, Italy.
Mirella BruttiniMedical Genetics, University of Siena, Siena, Italy.
Jill A HollenbachDepartment of Neurology, UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA.
Audrey E HendricksDepartment of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Ilaria MeloniMedical Genetics, University of Siena, Siena, Italy.
Francesco NovelliDepartment of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
GEN-COVID Multicenter Study Group
Alessandra RenieriMedical Genetics, University of Siena, Siena, Italy.
Simone FuriniMed Biotech Hub and Competence Center, Department of Medical Biotechnologies, University of Siena, Siena, Italy.
Paul J NormanDepartment of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA.ORCID 0000-0001-8370-7703
Antonio AmorosoImmunogenetics and Transplant Biology, Azienda Ospedaliera Universitaria, Città della Salute e della Scienza di Torino, Turin, Italy.
University of Siena · ITUniversity of Colorado Denver · USUniversity of Turin · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITUniversity of California, San Francisco · USStatistical and Applied Mathematical Sciences Institute · US

Funding

Natural Killer cells and the Immunogenetics of COVID-19R01AI158410 · NIAID · UNIVERSITY OF COLORADO DENVER · PI NORMAN, PAUL JOHN · 2021 to 2024
$2.9M
NIAID NIH HHS R01 AI158410NIH HHS R01 AI158410
6 · The paper itself

Abstract

Extreme polymorphism of HLA and killer-cell immunoglobulin-like receptors (KIR) differentiates immune responses across individuals. Additional to T cell receptor interactions, subsets of HLA class I act as ligands for inhibitory and activating KIR, allowing natural killer (NK) cells to detect and kill infected cells. We investigated the impact of HLA and KIR polymorphism on the severity of COVID-19. High resolution HLA class I and II and KIR genotypes were determined from 403 non-hospitalized and 1575 hospitalized SARS-CoV-2 infected patients from Italy collected in 2020. We observed that possession of the activating KIR2DS4*001 allotype is associated with severe disease, requiring hospitalization (OR = 1.48, 95% CI 1.20-1.85, p

Indexed as

COVID-19HLA-DP beta-ChainsAllelesAutoantibodiesGenotypeHumansReceptors, KIRSARS-CoV-2AutoantibodiesHLA-DPB1 antigenHLA-DP beta-ChainsKIR2DS4 protein, humanReceptors, KIRCOVID-19HLA class IIHLA-DPB1IFN-α antibodiesKIR2DS4

Identifiers

PMID37850268
PMCPMC10873037
OpenAlexW4387728529

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.